Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.70−0.06 (-1.60%)
Close on Nov 17, 2026Market cap $464.39MP/E –Yield –
Aquestive Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Aquestive Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.89M, down 19.1% year over year. For fiscal 2025 it was $17.19M, down 15.2% from the year before. The highest annual figure on record is $23.11M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.19M | -15.2% |
| FY2024 | Dec 31, 2024 | $20.28M | +54.8% |
| FY2023 | Dec 31, 2023 | $13.10M | -25.0% |
| FY2022 | Dec 31, 2022 | $17.48M | +2.5% |
| FY2021 | Dec 31, 2021 | $17.05M | -14.3% |
| FY2020 | Dec 31, 2020 | $19.89M | -3.3% |
| FY2019 | Dec 31, 2019 | $20.57M | -11.0% |
| FY2018 | Dec 31, 2018 | $23.11M | +4.4% |
| FY2017 | Dec 31, 2017 | $22.13M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.96M | -3.5% |
| Q1 FY2026 | Mar 31, 2026 | $4.20M | -21.6% |
| Q4 FY2025 | Dec 31, 2025 | $3.20M | -35.0% |
| Q3 FY2025 | Sep 30, 2025 | $4.53M | -14.0% |
| Q2 FY2025 | Jun 30, 2025 | $4.11M | -1.4% |
| Q1 FY2025 | Mar 31, 2025 | $5.36M | -9.6% |
| Q4 FY2024 | Dec 31, 2024 | $4.92M | +70.3% |
| Q3 FY2024 | Sep 30, 2024 | $5.27M | +64.9% |
| Q2 FY2024 | Jun 30, 2024 | $4.16M | +19.8% |
| Q1 FY2024 | Mar 31, 2024 | $5.93M | +67.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.89M | -32.5% |
| Q3 FY2023 | Sep 30, 2023 | $3.20M | -1.1% |
| Q2 FY2023 | Jun 30, 2023 | $3.47M | -33.2% |
| Q1 FY2023 | Mar 31, 2023 | $3.55M | -25.7% |
| Q4 FY2022 | Dec 31, 2022 | $4.28M | -2.8% |
| Q3 FY2022 | Sep 30, 2022 | $3.23M | -31.6% |
| Q2 FY2022 | Jun 30, 2022 | $5.20M | +22.0% |
| Q1 FY2022 | Mar 31, 2022 | $4.77M | +30.4% |
| Q4 FY2021 | Dec 31, 2021 | $4.40M | -0.6% |
| Q3 FY2021 | Sep 30, 2021 | $4.73M | -34.9% |
| Q2 FY2021 | Jun 30, 2021 | $4.26M | +10.8% |
| Q1 FY2021 | Mar 31, 2021 | $3.66M | -16.0% |
| Q4 FY2020 | Dec 31, 2020 | $4.43M | +44.7% |
| Q3 FY2020 | Sep 30, 2020 | $7.26M | +43.4% |
| Q2 FY2020 | Jun 30, 2020 | $3.85M | -52.8% |
| Q1 FY2020 | Mar 31, 2020 | $4.35M | +1.2% |
| Q4 FY2019 | Dec 31, 2019 | $3.06M | -46.2% |
| Q3 FY2019 | Sep 30, 2019 | $5.06M | +3.3% |
| Q2 FY2019 | Jun 30, 2019 | $8.15M | +30.0% |
| Q1 FY2019 | Mar 31, 2019 | $4.30M | -24.3% |
| Q4 FY2018 | Dec 31, 2018 | $5.68M | +17.5% |
| Q1 FY2018 | Mar 31, 2018 | $4.90M | – |
| Q4 FY2017 | Dec 31, 2017 | $6.27M | – |
| Q3 FY2017 | Sep 30, 2017 | $5.68M | – |
| Q2 FY2017 | Jun 30, 2017 | $4.84M | – |
See a number that looks wrong?